Sage Therapeutics, Inc. financial data

Symbol
SAGE on Nasdaq
Industry
Pharmaceutical Preparations
Location
215 First Street, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - Apr 25, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 968 % -35.4%
Debt-to-equity 11.4 % +51.7%
Return On Equity -60.9 % -43.8%
Return On Assets -54.7 % -38.8%
Operating Margin -595 % +90.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.2M shares +0.7%
Common Stock, Shares, Outstanding 60.2M shares +0.7%
Entity Public Float 2.47B USD +46.6%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.1M shares +0.77%
Weighted Average Number of Shares Outstanding, Diluted 60.1M shares +0.77%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 91.1M USD +869%
Research and Development Expense 335M USD -1.71%
Operating Income (Loss) -542M USD +6.42%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -541M USD -1.63%
Net Income (Loss) Attributable to Parent -503M USD +9.76%
Earnings Per Share, Basic -8.39 USD/shares +10.5%
Earnings Per Share, Diluted -8.39 USD/shares +10.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 173M USD -16.4%
Marketable Securities, Current 544M USD -41%
Accounts Receivable, after Allowance for Credit Loss, Current 10.5M USD
Assets, Current 755M USD -37.2%
Property, Plant and Equipment, Net 1.59M USD -40.5%
Operating Lease, Right-of-Use Asset 2.86M USD -68.5%
Other Assets, Noncurrent 6.22M USD +46.1%
Assets 768M USD -37.1%
Accounts Payable, Current 6.48M USD -47.2%
Employee-related Liabilities, Current 7.09M USD -28.2%
Accrued Liabilities, Current 52M USD -19.7%
Liabilities, Current 61.8M USD -27%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 61.8M USD -29.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -787K USD +84.5%
Retained Earnings (Accumulated Deficit) -2.68B USD -23.1%
Stockholders' Equity Attributable to Parent 706M USD -37.7%
Liabilities and Equity 768M USD -37.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.8M USD +75.4%
Net Cash Provided by (Used in) Financing Activities 1.56M USD -41.7%
Net Cash Provided by (Used in) Investing Activities 139M USD -28.4%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 60.2M shares +0.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 103M USD +135%
Deferred Tax Assets, Valuation Allowance 735M USD +23.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 735M USD +23.9%
Operating Lease, Liability 5.17M USD -57.4%
Depreciation 336K USD +4.03%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -499M USD +9.54%
Property, Plant and Equipment, Gross 9.41M USD +4.63%
Operating Lease, Liability, Current 3.31M USD -57%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 429M USD +23.3%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 7.74M USD +13.1%
Operating Lease, Payments 7.64M USD +2.34%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 67M USD +6.25%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%